Publications by authors named "Rebecca C Prajogo"
Article Synopsis
- Tyrosine kinase inhibitors (TKIs) are the main treatment for non-small cell lung cancer (NSCLC) with EGFR mutations, but resistance to these drugs often develops due to new mutations and they can cause severe side effects.
- Researchers are exploring customized antisense oligonucleotides (ASOs) to specifically target these mutations, using extracellular vesicles to deliver them directly to cancer cells.
- Preliminary results show that ASOs can effectively reduce tumor growth in models of NSCLC and may work better than TKIs, offering a promising new treatment approach tailored to individual genetic profiles.
Immunotherapy has emerged as a mainstay in cancer therapy, yet its efficacy is constrained by the risk of immune-related adverse events. In this study, we present a nanoparticle-based delivery system that enhances the therapeutic efficacy of immunomodulatory ligands while concurrently limiting systemic toxicity. We demonstrate that extracellular vesicles (EVs), lipid bilayer enclosed particles released by cells, can be efficiently engineered via inverse electron demand Diels-Alder (iEDDA)-mediated conjugation to display multiple immunomodulatory ligands on their surface.
View Article and Find Full Text PDFThe COVID-19 pandemic has resulted in a large number of fatalities and, at present, lacks a readily available curative treatment for patients. Here, we demonstrate that unmodified red blood cell-derived extracellular vesicles (RBCEVs) can inhibit SARS-CoV-2 infection in a phosphatidylserine (PS) dependent manner. Using T cell immunoglobulin mucin domain-1 (TIM-1) as an example, we demonstrate that PS receptors on cells can significantly increase the adsorption and infection of authentic and pseudotyped SARS-CoV-2 viruses.
View Article and Find Full Text PDF